L
LB Pharmaceuticals
Biotech & Life Sciences · New York City, United States · Founded 2015
LB is focused on the multi-billion dollar US antipsychotic market and is developing a proprietary MoreLess
LB Pharmaceuticals Inc., established in 2015, is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company directs its resources towards addressing significant unmet needs in the neuropsychiatric space. The company was founded by Zachary Prensky, who serves as President and CEO, and Dr. Robert M. Berman. Prensky brings a background in life sciences investment and venture capital, having co-founded a merchant bank and managed a life sciences fund. Dr. Berman, who acts as the Chief Medical Officer, has an extensive career in neuroscience clinical development, holding senior positions at major pharmaceutical firms like Bristol-Myers Squibb and Pfizer and contributing to the development of notable CNS drugs such as Abilify.
The company's primary business revolves around the clinical development and potential commercialization of its lead product candidate, LB-102 (N-methyl-D-aspartate, or NMDA, receptor glycine-site partial agonist). This compound is being investigated for the treatment of schizophrenia and other neuropsychiatric conditions. LB Pharmaceuticals operates on a milestone-driven business model typical of the biopharmaceutical industry, where value is created through the progression of its drug candidates through the rigorous phases of clinical trials. Funding is primarily secured through private placements and venture capital investments to support its research and development activities, including a $18 million Series A financing round.
LB-102 is designed as a adjunctive therapy, intended to be used alongside standard antipsychotic treatments for schizophrenia. Its mechanism of action targets the glycine site of the NMDA receptor, aiming to improve cognitive deficits and negative symptoms associated with the condition, which are often not adequately addressed by current medications. The company has advanced LB-102 into Phase 2 clinical trials to evaluate its efficacy and safety. A key differentiating factor for LB-102 is its potential to offer a better safety profile, particularly concerning over-excitation of the NMDA receptor, a risk observed with other full agonists.
Keywords: biopharmaceutical, CNS disorders, schizophrenia, clinical-stage, neuropsychiatry, adjunctive therapy, NMDA receptor, drug development, neuroscience, mental health
Company overview
LB Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- New York City, United States
- Employees
- 1
- Open positions
- 2
- Dealroom signal
- 60.3
Valuation & funding
LB Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Feb 2026 | $100M | — | Balyasny Asset Management · Pivotal BioVenture Partners · TCGX · Spruce Street Capital | ↗ |
| IPOOther financing | Sep 2025 | $285M | $381M | Undisclosed | ↗ |
| SERIES COther financing | Jan 2024 | $75M | $300M | Undisclosed | ↗ |
| CONVERTIBLEOther financing | Sep 2023 | $40M | — | Undisclosed | ↗ |
| LATE VCOther financing | Sep 2023 | $35M | $140M | Undisclosed | ↗ |
| LATE VCOther financing | Nov 2022 | Tarnagulla Ventures | ↗ | ||
| CONVERTIBLEOther financing | Sep 2020 | Undisclosed | ↗ | ||
| SERIES AOther financing | Mar 2019 | Rivopharm | ↗ | ||
| EARLY VCOther financing | Nov 2018 | Undisclosed | ↗ | ||
| EARLY VCOther financing | Dec 2017 | Undisclosed | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$31M | — |
| 2025 | $0 | — | −$31M | — |
| 2024 | $0 | — | −$63M | — |
| 2023 | $0 | — | −$11M | — |
| 2022 | $0 | — | −$2.7M | — |
Growth signals
LB Pharmaceuticals website traffic
Latest recorded traffic for LB Pharmaceuticals is 5.1K monthly website visits, up 45.7% over the last three months.
Hiring
Open positions at LB Pharmaceuticals
Current openings linked to this company in Dealroom.
Comparisons
LB Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
LB Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Investors
11 investors on LB Pharmaceuticals's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where LB Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about LB Pharmaceuticals
Recent press, funding announcements, and product moves mentioning LB Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about LB Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about LB Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LB Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.